Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey
Clemente Ponzetti,1 Monica Canciani,2 Massimo Farina,2 Sara Era,3 Stefan Walzer4,5 1Group Policlinic Monza, Alessandria, National Scientific Associazione Nazionale dei Medici delle Direzioni Ospedaliere (National Association of Hospital Physicians), Bologna, 2Studio EmmEffe S.r.l, Milan, 3Roche S.p....
Main Authors: | Ponzetti C, Canciani M, Farina M, Era S, Walzer S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-05-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/potential-resource-and-cost-saving-analysis-of-subcutaneous-versus-int-peer-reviewed-article-CEOR |
Similar Items
-
Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
by: Delgado Sánchez O, et al.
Published: (2019-11-01) -
Elemental mercury poisoning caused by subcutaneous and intravenous injection: An unusual self-injury
by: Jaywant Wale, et al.
Published: (2010-04-01) -
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021-05-01) -
Comparative study of the adverse effects of subcutaneous and intraveneous infusion in patients admitted to neurology ward
by: Simin Jahani, et al.
Published: (2009-10-01) -
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency
by: Andrea Visentin, et al.
Published: (2022-12-01)